New pill for rheumatoid arthritis passes first safety check in small study

NCT ID NCT05858788

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study tested a new oral drug called SAR441566 in 10 healthy Japanese men to see how safe it is and how the body processes it. The drug is being developed for rheumatoid arthritis, an autoimmune disease that causes joint pain and swelling. The study only looked at safety and drug levels in the blood, not whether it actually treats arthritis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR441566 (oral tablet)
What this could lead to: If successful, this could lead to a new oral treatment option for rheumatoid arthritis, helping control the disease with fewer side effects.
What could go wrong: This is a very early Phase 1 study in only 10 healthy men, not patients. It only checks safety and drug levels, not whether it works for arthritis. Many drugs fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Parexel International-Site Number:8400001

Glendale, California, 91206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.